COMPARATIVE ANALYSIS OF GLIMEPIRIDE AND GLICLAZIDEMR USE IN TYPE 2 DIABETES MELLITUS TREATMENT

Authors

  • Kravchun N. A. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv
  • Khyzhnyak O. O. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv https://orcid.org/0000-0002-4541-5248

DOI:

https://doi.org/10.21856/j-PEP.2010.1.01

Keywords:

diabetes mellitus, treatment, Glymepyride, GliclazideMR

Abstract

Results of the hypoglycemic therapeutic efficiency of Gliclazide and Glimepiride in patients with type 2 diabetes mellitus are represented in the open prospective study. Daily dose of GliclazideMR was 90 mg, and Glimepiride — 4 mg. It is evident that third-generation sulfonylurea — Glimepiride has more protective cardiovascular effects because it significantly decreases microalbumiurea. Moreover, it significantly improves postprandial and basal glycemia, and the HDLP cholesterol level in patients with 5-year DM2 history. As an anti-diabetic drug Glimepiride has some advantages with regard to a high risk of microvascular complications when the disease is in progress.

References

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy [Text] / A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. — 2008. — Vol. 31, № 12.

Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes [Text] / S. Schwartz, V. Fonseca, B. Berner [et al.] // Diabetes Care. — 2006. — Vol. 29, № 4.

Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ [Текст]: рук. для практикующих врачей / И. И. Дедов [и др.]; под общ. ред. И. И. Дедова, Г. А. Мельниченко. — М.: Литтерра, 2006. — Т. 12. — С. 41–49.

Müller G. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes [Text] / G. Müller, K. // Geisen. Horm. Metabol. Res. — 1996. — Vol. 28 (9). — P. 469–87.

Rosskamp R. Clinical profile of the novel sulphonylurea glimepiride [Text] / R. Rosskamp, K. Wernicke-Panten, E. Draeger // Diabetes. Res. Clin. Pract. — 1996. — Vol. 31. — S33–42.

Балаболкин М. И. Лечение сахарного диабета и его осложнений [Текст]: учеб. пособие / М. И. Балаболкин, Е. М. Клебанова, В. М. реминская. — М.: ОАО «Изд-во Медицина», 2005. — С. 151–256.

Influence of oral sulfonylurea agents on hepatic glucose uptake [Text] / R. Kawamori, T. Morishima, M. [et al.] // Diabetes Res. Clin. Pract. — 1995. — Vol. 28. — S 109–13.

Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus [Text] / D. Y. Xu, S. P. Zhao, Q. X. Huang [et al.] // Diabetes Res. Clin. Pract. — 2009. — Vol. 30.

Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents [Text] / S. T. de Dios, K. V. Frontanilla, J. Nigro, [et al.] // J. Diabetes Compl. — 2007. — Vol. 21 (2). — P. 108–17.

Holstein A. Glimeperide induces a lower incidence of severe hypoglycemia in patients with type 2 diabetes than glibenclamide [Text] / A. Holstein, A. Plashke, E-H. Egbert // Hypoglicemia from research to practice. Asisi, Italy. — 2001. — № 26–29. — Abstracts 41.

Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience [Text] / W. B. Kannel, R. B. D’Agostino, P.W. Wilson [et al.] // Am. Heart. J. — 1990. — Vol. 120. — P. 672–676.

Classification of hyperlipidemias and hyoperlipoproteinemias [Text] / J. L. Beaumot, L. A. Carlson, G. R. Cooper [et al.] // Bull. WHO. — 1970. — Vol. 43. — P. 891.

Климов А. Н. Обмен липидов и липопротеидов и его нарушения [Текст] / А. Н. Климов, Н. Г. Никуличева. — СПб.: Питер Ком, 1999. — 512 с.

Downloads

Published

2010-03-03

How to Cite

Kravchun, N. A., & Khyzhnyak, O. (2010). COMPARATIVE ANALYSIS OF GLIMEPIRIDE AND GLICLAZIDEMR USE IN TYPE 2 DIABETES MELLITUS TREATMENT. Problems of Endocrine Pathology, 31(1), 5-11. https://doi.org/10.21856/j-PEP.2010.1.01

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 5 > >>